



July 31, 2024

CORRESPONDENCE FILED VIA EDGAR

Office of Life Sciences
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Daniel Crawford

**Re: Acasti Pharma Inc.
Registration Statement on Form S-4 (File No. 333-280536)
Request for Acceleration of Effective Date**

Dear Mr. Crawford:

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Acasti Pharma Inc. (the “**Company**”) hereby respectfully requests that the U.S. Securities and Exchange Commission accelerate the effective date and time of the above referenced Registration Statement on Form S-4 (the “**Registration Statement**”) and declare the Registration Statement effective as of 4:00 p.m. Eastern Time on August 2, 2024, or as soon thereafter as practicable.

The Company requests that it be notified of such effectiveness by a telephone call to Steven Abrams of Hogan Lovells US LLP at (267) 675-4671.

[Signature page follows]

Sincerely,

Acasti Pharma Inc.

/s/ Prashant Kohli

Prashant Kohli

Chief Executive Officer and Director
